Send to

Choose Destination
Curr Med Chem. 2019 Mar 25. doi: 10.2174/0929867326666190326111851. [Epub ahead of print]

Carnosine and diabetic nephropathy.

Author information

Centre for Pediatric and Adolescent Medicine, University of Heidelberg, Heidelberg. Germany.
Vth Department of Medicine (Nephrology/Endocrinology/Rheumatology) University Medical Center Mannheim, University of Heidelberg. Germany.


Diabetic nephropathy (DN) is a major complication in patients with type 1 or type 2 diabetes and represents the leading cause of end-stage renal disease. Current therapeutic options, hyperglycemia and blood pressure control, use of a statins and renin-angiotensin-aldosterone blockers, to some extent retard progression, but do not prevent the development of DN. Novel therapeutic approaches are therefore warranted. In view of a polymorphism in the carnosinase 1 gene CNDP1, resulting in reduced carnosine degradation activity and a significant DN risk reduction, carnosine (β-alanyl-L-histidine) has gained attention as a potential therapeutic target. Carnosine has anti-inflammatory, antioxidant, anti-glycation and reactive carbonyl quenching properties. In diabetic rodents, carnosine supplementation consistently improved renal histology and function and in most studies, also glucose metabolism. Even though plasma half-life of carnosine in humans is short, first intervention studies in (pre-) diabetic patients yielded promising results. The precise molecular mechanisms of carnosine mediated protective action, however, are still incompletely understood. This review highlights the recent knowledge on the role of the carnosine metabolism in DN.


CNDP1; Carnosine; diabetic nephropathy; end-stage renal disease; histidine-containing dipeptides; polymorphism

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center